Europe Automated Breast Ultrasound Systems Market size surpassed USD 360 million in 2021 and is projected to expand at 11% CAGR between 2022 and 2028.
Get more details on this report - Request Free Sample PDF
Rising prevalence of breast cancer the key factor influencing the market demand. For women, breast cancer is one of the commonly diagnosed cancers across the region. Early detection and proper treatment through screening are the most important means to improve the survival rate of patients. With the burden of breast cancer in the region growing, tailor-made treatments and therapies are becoming popular across healthcare establishments.
To satisfy this demand for personalized solutions, leading companies are consistently investing in R&D to launch advanced ABUS in the market. The introduction of imaging technology that creates 3D pictures, for example, is a breakthrough in healthcare that derives high-quality breast cancer screening and diagnosis for enhanced patient care.
Europe Automated Breast Ultrasound Systems (ABUS) Market, By Product
Rising breast cancer occurrences, an expanding radiology market, and increased patient awareness of the relationship between breast density and breast cancer are driving demand for ABVS. Technological advancements in the development of new imaging techniques, as well as increasing government funding for breast cancer awareness are expected to impact the system applications.
Europe Market, By Country
UK automated breast ultrasound systems market will record over 12% growth rate during the forecast timeline. There are around 55,900 new breast cancer cases in the UK every year, which equates to a 150 every day. Such growing prevalence of the disease ranks it among the most common types of cancers in the UK, accounting for 15% of all new cancer cases per year. Robust public healthcare services in the country and presence of major health insurance providers will strengthen the industry outlook.
Europe Market, By End-User
The hospital end-user segment will witness a lucrative growth rate through 2028. The region has seen a consistent growth in infrastructure development at hospitals. An increasing awareness about dense breast tissues will encourage patients to opt for early diagnosis. Availability of sophisticated infrastructure along with skilled professionals are the major reasons augmenting patient footfall across hospital set-ups. Strong presence of healthcare systems, including the NHS in the UK, and the availability of suitable health insurance policies in countries such as Germany and France will reinforce the utilization of ABUS in hospitals.
Competitive Industry Landscape
Some of the leading companies involved in the Europe automated breast ultrasound systems market include QView Medical Inc., Koninklijke Philips N.V., GE Healthcare, CapeRay Medical Ltd, Hitachi Ltd., SonoCine Inc., and Siemens AG.
The organizations will keep investing in R&D efforts to bring advanced diagnostic capabilities to breast cancer patients, representing key industry trends. The integration of modern technologies such as artificial intelligence (AI) to speed up diagnostic results and deliver enhanced accuracy could foster the market size.